Rahul K Dhanda is a founder and is the president and chief executive officer of Sherlock Biosciences. He also serves on the company’s Board of Directors. Most recently, Mr. Dhanda spent 10 years at T2 Biosystems where he helped grow the company from an early-staged, venture-backed startup to a commercial, publicly-traded leader in infectious disease diagnostics where he held the role of senior vice president of corporate development and marketing. At T2 Biosystems, he had an expansive role where he led the company’s strategy, marketing, product management and all corporate deal activity, the latter of which brought over $40 million in funding to the company.

Sekar Kathiresan is a preventive cardiologist who has made groundbreaking discoveries of cardioprotective genetic mutations, which confer resistance to cardiovascular disease. He is director of the Massachusetts General Hospital (MGH) Center for Genomic Medicine and the Ofer and Shelly Nemirovsky MGH Research Scholar, director of the Cardiovascular Disease Initiative at the Broad Institute, and professor of medicine at Harvard Medical School. Dr. Kathiresan’s research laboratory focuses on understanding the inherited basis for blood lipids and myocardial infarction and using these insights to improve preventive cardiac care. For his research contributions, he has been honored with a Distinguished Scientist Award from the American Heart Association and the 2018 Curt Stern Award from the American Society of Human Genetics. In tandem with his research, his clinical focus is the primary prevention of myocardial infarction in individuals with a family history of heart attack. He graduated summa cum laude with a B.A. in history from the University of Pennsylvania and received his M.D. from Harvard Medical School. Dr. Kathiresan completed his clinical training in internal medicine and cardiology at MGH and his postdoctoral research training in human genetics at the Framingham Heart Study and the Broad Institute.

Jessica is a Managing Director in KPMG’s Healthcare and Life Sciences Strategy practice. Jessica started her career conducting bench research in synthetic biology and tissue engineering at UC Berkeley and UC San Diego and in drug encapsulation at Amylin Pharmaceuticals. She then earned an MS in mechanical engineering (focused on biomechanics) and an MBA, both from MIT. Since then, she has focused on helping pharma, diagnostics, private equity, and other clients grow their life sciences businesses both organically and inorganically. Prior to the COVID-19 pandemic, much of Jessica’s work focused on diagnostics. During this pandemic, she has leveraged her diagnostics expertise to support reference labs as they setup and scale up COVID-19 testing to hundreds of thousands of tests per day. She is also advising employers, universities, sport teams, and health systems on COVID-19 testing strategy and implementation.

Dr. Miller is a Market Sector Leader in the Mass General Brigham Innovation office. Dr. Miller has 30 years of experience in the clinical laboratory industry and personalized medicine field including serving as Vice President and Head of Personalized Healthcare and Biomarker Strategy, Portfolio and Alliances for AstraZeneca Pharmaceuticals; Executive Vice President and Chief Technology Officer of MolecularMD; and Vice President and General Manager of Genzyme Analytical Services. Dr. Miller also serves as Chair of the Scientific Advisory Board and is a member of the Board of Directors of the medical device company, Biomarker Strategies. He received his Ph.D. in Experimental Pathology from Roswell Park Memorial Institute, a graduate division of the State University of New York at Buffalo. He completed his postdoctoral work in molecular hematology and viral leukemogenesis at Memorial Sloan Kettering Cancer Center and molecular genetics at the University of Miami School of Medicine.

Kristin is the head of HCLS strategy at KPMG, and the global healthcare and life sciences deal advisory leader. She has 25 years of experience in research and strategy consulting and M&A diligence in medical innovation and the healthcare and life sciences industry. Her primary areas of focus are deal advisory and corporate strategy for pharmaceutical, diagnostics, and consumer health companies, investors, and medical institutions worldwide. She is a noted speaker, workshop leader, and writer in the life sciences industry. She is also a leader in clinical laboratory and medical innovation, developing product and service strategies, operations, and global deals with on-the-ground experience in North America, Latin America, Europe, Asia, India, the Middle East, and the Caribbean. Her book, Personalizing Precision Medicine, was a clinical best seller and has garnered attention worldwide for its all-inclusive and comprehensive look at global precision medicine. Kristin also works with health systems and affiliated organizations on their innovative services strategies, diligences, and operations, including clinical laboratory builds, health IT, hospital services, and clinical outreach strategy. Kristin is on our KPMG Restart America task force and develops COVID-19 diagnostic and other service programs for large employers, institutions, and regions seeking recovery.

Greg Welch is a human resources director with over 30 years of progressive experience in human resource management. His industry experience includes professional services consulting and applied research organizations, including Accenture, Hitachi Consulting and MIT Lincoln Laboratory, Charles Stark Draper Laboratory and currently the Broad Institute of MIT and Harvard. Greg currently manages the HR Business Partner team at the Broad Institute MIT and Harvard.